Summary of cost-effectiveness after 1 year of treatment
| Treatment | $ per MH achieved | $ per 1 additional MH achieved |
|---|---|---|
| Infliximab 5 mg/kg every 8 weeks | $99 171 | – |
| Infliximab 10 mg/kg every 8 weeks | $123 653 | $1 243 310 |
| Adalimumab 160/80/40 mg, 40 mg EOW | $316 378 | (Dominated) |
| Vedolizumab 300 mg every 8 weeks | $301 969 | (Dominated) |
EOW, every other week; MH, mucosal healing.